C. Ola Landgren, Leader, Translational and Clinical Oncology Program/Experimental Therapeutics at Sylvester Comprehensive Cancer Center, shared a post on LinkedIn:
“We are thrilled to welcome Dr. Rafat Abonour and Dr. Gil Hevroni aboard as clinical faculty at Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, in beautiful Miami!
Sylvester Myeloma Institute is growing rapidly. With our latest recruits we provide world-class myeloma care – plus full access to a comprehensive myeloma clinical trials portfolio – at the following outpatient locations:
- Miami (Sylvester Comprehensive Cancer Center and Griffin Clinical Research Building)
- Coral Gables (Lennar Foundation)
- Doral
- Aventura (Sole Mia)
- Deerfield
As well as our inpatient service at UHealth Tower in Miami.
Stay tuned – we will continue to expand to meet the increasing needs.
Sylvester Comprehensive Cancer Center is the only NCI-designated cancer center in South Florida. Our catchment area is over 6.4 million people. The Division of Myeloma and Myeloma Research Institute provides world-class care to a large number of myeloma patients in Miami, across the U.S., and internationally.
Our clinical trials portfolio is extensive; focusing on Phase 1 and Phase 2 clinical trials, we bring all the latest anti-myeloma drugs to our patients. Our world-class computational discovery research laboratory as well as our world-class epigenetic research wet laboratory are leading many innovative research studies, and we collaborate with other major centers worldwide.
Florida has the highest number of newly diagnosed multiple myeloma patients among the 50 states in the U.S. Over 10% of all newly diagnosed patients in the U.S. are diagnosed in Florida. With Miami being the largest city in the state, we are committed to provide world-class care for large numbers of patients within our catchment area. We also see a large number of international multiple myeloma patients and patients from other states across the U.S. Ultimately, we are seeking to develop curative strategies for multiple myeloma.”
More posts featuring C. Ola Landgren.